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Pityriasis rosea following influenza (H1N1) vaccination
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Received May 3, 2010; accepted November 13, 2010AbstractPityriasis rosea is a distinct papulosquamous skin eruption that has been attributed to viral reactivation, certain drug exposures or rarely,
vaccination. Herein, we reported a clinicopathlogically typical case of pityriasis rosea that developed after the H1N1 vaccination. With a global
H1N1 vaccination program against the pandemic H1N1 influenza, patients should be apprised of the possibility of such rare but benign skin
reaction to avoid unnecessary fear. Furthermore, a brief review of the current reported skin adverse events related to the novel H1N1 vaccination
in Taiwan is presented here.
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Pityriasis rosea (PR) is an acute, self-limited, papulosqu-
amous skin eruption that occurs most commonly among
teenagers and young adults.1 Typical clinical presentation is
the appearance of the primary herald patch followed by the
onset of secondary scaly skin eruptions characteristically
distributed along the skin tension line within days to weeks.2
Although PR is a well-known and relatively common
disease, its cause is still not completely understood. We report
a case of PR occurring after H1N1 vaccination. This case may
offer an example of possible skin adverse reaction associated
with this “new vaccine” and in addition raise issues about the
etiopathogenesis of vaccination-associated PR.
2. Case report
A 25-year-old male presented to our dermatology clinic for
evaluation of a skin rash on his trunk and proximal limbs which
had been present for two weeks. The patient described that* Corresponding author. Dr. Wei-Ming Wang, Department of Dermatology,
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followed several days later by the onset of many itchy scaly
lesions on his trunk and proximal extremities. The first herald
patch developed five days after he underwent H1N1 vaccina-
tion (AdimFlu-S (A-H1N1), Adimmune, Taichung, Taiwan).
There were no systemic symptoms such as fever, malaise,
myalgia or loss of appetite. He had no history of egg allergies,
recent infection or drug exposure. He also denied any personal
or family history of similar skin eruptions. On physical
examination, the herald patch on his left upper thigh showed
a 3-cm oval thin plaque with a central, wrinkled, erythematous
area and a salmon-colored peripheral zone. There was a fine
collarette of scale inside the peripheral zone (Fig. 1). The
secondary eruptions were numerous, discrete, 1e3 cm in
diameter, oval to round, salmon-colored plaques with similar
collarette of scale that looked like the primary herald patch in
miniature. The distribution of these secondary plaques was
along the lines of cleavage that assumed a Christmas tree
pattern on the patient’s trunk (Fig. 2). Skin biopsy obtained
from one trunk lesion demonstrated patchy parakeratosis,
reduced granular cell layer, mild acanthosis and mild spon-
giosis. The superficial dermis revealed slight papillary edema,
perivascular and superficial dermal interstitial infiltrate of
lymphocytes and histiocytes (Fig. 3). The diagnosis of PR was
made because of the typical clinicopathologic features. He washinese Medical Association. All rights reserved.
Fig. 1. A herald patch on the left upper thigh demonstrated an oval to round
central, wrinkled, erythematous area and a salmon-colored peripheral zone.
Inside the peripheral zone, there was a fine collarette of scale.
Fig. 3. The histopathologic findings of the lesional biopsy showed patchy
parakeratosis, reduced granular cell layer, mild acanthosis and mild spongio-
sis. The superficial dermis revealed slight papillary edema, perivascular and
superficial dermal instersitial infiltrate of lymphocytes and histiocytes.
(Hematoxylin and eosin. Original magnification 100).
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cream. At the scheduled 2-week follow-up visit, the itch
symptoms as well as the skin lesions were improved.
3. Discussion
Influenza is a highly infectious respiratory disease that may
potentially cause considerable morbidity and mortality in highFig. 2. Secondary plaques along the lines of cleavage on the trunk.risk populations. The outbreak because of a new strain of
influenza A virus subtype H1N1 began in the state of Veracruz,
Mexico in early 2009. In response to the ongoing global flu
pandemic, the Taiwan Central Epidemic Command Center has
conducted a mass vaccination program since November 1,
2009. The number of individuals receiving H1N1 vaccination
in Taiwan had reached 5,641,315 as of February 8, 2010, with
24% coverage of the total population.3
We analyzed the data retrieved from the Taiwan Centers for
Disease Control of suspected H1N1 vaccine-related adverse
events weekly summary reports database dated from
November 1, 2009 to February 4, 2010.4 The total number of
suspected adverse events attributed to H1N1 vaccination was
1247. Among them, the skin adverse events comprised 260
cases, which was around 21% of the total reported adverse
events (Table 1). The most commonly reported solicited
adverse events in other clinical trials were injection site
reaction such as pain or erythema.5 Unlike the data reported
from other countries, the most reported adverse skin reaction
in Taiwan was unspecified skin rash, comprising 53.8%, fol-
lowed by injection site reaction, which reached 19.6%. The
lower incidence of injection site reaction in Taiwan may result
from the underreporting of these minor events. The incidence
of both urticaria and angioedema was approximately 14%. The
remaining skin adverse events were the minority, including
unspecified pruritus, mouth ulceration, exfoliative rash,
vasculitis, cellulitis, blister or vesicular rash, herpes infection,
ecchymosis, petechiae, skin discoloration, alopecia, folliculitis
and unspecified dermatitis. No serious adverse skin reactions
such as Stevens-Johnson syndrome or toxic epidermal nec-
rolysis had been reported so far.
PR is an acute, self-limited skin disease characterized by
distinct cutaneous eruptions; namely an oval, salmon-colored,
scaly herald patch followed by a secondary phase manifesting
as similar smaller rose- or salmon-colored scaling patches
Table 1
Statistical data of suspected vaccine-related skin adverse events after H1N1
vaccination from Taiwan Centers for Disease Control dated from November 1,
2009 to February 4, 2010
Number of
cases reported
Percentage (%)
Unspecified skin rash 140 53.8
Injection site reaction (reported as
erythema, swelling, induration, cyst,
mass formation, injection site pain,
pruritus and anesthesia)
51 19.6
Urticaria 19 7.3
Angioedema (including orbital, auricular,
lip, facial edema)
18 6.9
Unspecified pruritus 5 1.9
Mouth ulceration 4 1.5
Exfoliative rash 4 1.5
Purpura 4 1.5
Vasculitis 3 1.2
Cellulitis 2 0.77
Blister or vesicular rash 2 0.77
Herpes virus infection 2 0.77
Ecchymosis 1 0.38
Petechiae 1 0.38
Skin discoloration 1 0.38
Alopecia 1 0.38
Folliculitis 1 0.38
Unspecified dermatitis 1 0.38
Total number of cases reported 260 e
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Christmas tree pattern (a unique pattern with their long axes
along the cleavage lines of the skin).2 The genuine patho-
genesis of PR remains obscure. However, more and more
scientific research has implicated that reactivation of human
herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7) may
contribute to the development of acute skin lesions. These
studies were critically appraised by Drago et al. in a recent
large review and concluded that a causative association
seemed likely.6 Numerous precipitating factors have been
identified as triggering the occurrence of PR. Among them, the
most commonly known are stress, acute illness, immunosup-
pressive state such as UV exposure or pregnancy.7 Further-
more, several drugs were incriminated for inducing PR-like
rashes, such as captopril, gold, barbiturates, isotretinoin,
metronidazole, clonidine, ergotamine, terbinafine, omepra-
zole, and tyrosine kinase inhibitors.2,8e11 As with the case
reported herein, PR may develop after vaccination. PR erup-
tions have been reported after smallpox, diphtheria, Bacille
Calmette-Gue´rin, pneumococcal and hepatitis B virus vacci-
nations.12e16 In our case, the patient had neither any of the
aforementioned precipitating factors nor recent drug exposure
before the skin eruptions. Furthermore, the skin rash devel-
oped within one week of vaccination: a causal relationship was
therefore highly suggested in our patient. The precise mech-
anism leading to PR after vaccination is unknown. However,
the reported cases have driven the hypothesis that vaccination-
induced immune stimulation may trigger the reactivation oflatent infectious agents such as HHV-6 or HHV-7 and subse-
quently the PR develops owing to the reactivation of viruses.
Another possible mechanism is cell-mediated immune
response related to a molecular mimicry with a viral epitope,
although there is currently no evidence to support such theory.
Further studies are necessary to confirm whether the influenza
vaccine is associated with the development of PR and what the
mechanism it is, if it is the case.
PR is a common skin disease to practicing dermatologists,
but may be unfamiliar to non-dermatologists. More than fifty
percent of unspecified skin rash is reported as adverse vaccine-
related skin reaction in Taiwan, which implies that a specific
diagnosis is rarely achieved. Taking the above into consider-
ation, the PR following vaccination is possibly far under-
estimated. With the worldwide vaccination campaign against
the pandemic flu, more and more physicians of different
specialities may become involved in the vaccination program.
We hope this case may serve as a reminder for both physicians
and patients of such rare but benign skin reaction, which may
be caused by the novel H1N1 vaccination.References
1. Browning JC. An update on pityriasis rosea and other similar childhood
exanthems. Curr Opin Pediatr 2009;21:481e5.
2. Chuh A, Lee A, Zawar V. Pityriasis rosea-an update. Indian J Dermatol
Venereol Leprol 2005;71:311e5.
3. http://www.h1n1.gov.tw/public/Data/0281026971.xls [accessed: 08.02.10].
4. http://www.h1n1.gov.tw/public/Data/02499171.xls [accessed: 08.02.10].
5. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J,
et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl
J Med 2009;361:2405e13.
6. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical
appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009;
61:303e18.
7. Drago F, Rebora A. Viral reactivation and skin eruptions. Dermatology
2003;207:1e2.
8. Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch
Dermatol 1982;118:186e7.
9. Aydogan K, Karadogan SK, Adim SB, Tunali S. Pityriasis rosea-like
eruption due to ergotamine: a case report. J Dermatol 2005;32:407e9.
10. Buckley C. Pityriasis rosea-like eruption in a patient receiving omepra-
zole. Br J Dermatol 1996;135:660e1.
11. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C,
et al. Pityriasis rosea-like eruption during treatment with imatinib mesy-
late: description of 3 cases. J Am Acad Dermatol 2005;53:S240e3.
12. Witherspoon FG, Thibodaux DJ. Pityriasis-rosea-like eruption following
smallpox vaccination. AMA Arch Dermatol 1957;76:109e10.
13. Laude TA. Herald patch in a DPT injection site. J Am Acad Dermatol
1981;5:475e6.
14. Honl BA, Keeling JH, Lewis CW, Thompson IM. A pityriasis rosea-like
eruption secondary to bacillus Calmette-Gue´rin therapy for bladder
cancer. Cutis 1996;57:447e50.
15. Sasmaz S, Karabiber H, Boran C, Garipardic M, Balat A. Pityriasis rosea-
like eruption due to pneumococcal vaccine in a child with nephrotic
syndrome. J Dermatol 2003;30:245e7.
16. De Keyser F, Naeyaert JM, Hindryckx P, Elewaut D, Verplancke P,
Peene I, et al. Immune-mediated pathology following hepatitis B vacci-
nation: two cases of polyarteritis nodosa and one case of pityriasis rosea-
like drug eruption. Clin Exp Rheumatol 2000;18:81e5.
